In an announcement Biocon Biologics Ltd knowledgeable that each biosimilar merchandise can be found in vial and prefilled pen shows and are interchangeable for the reference model, LANTUS® (insulin glargine), permitting for substitution on the pharmacy counter.
Commenting on the launch of each biosimilar merchandise in US, Shreehas Tambe, Deputy CEO, Biocon Biologics mentioned, “The launch of our interchangeable biosimilar insulin glargine in the U.S. by our partner Viatris, is in line with our aspiration to provide our biosimilar insulins to ‘one in five’ insulin dependent people with diabetes, globally. This is indeed a landmark event and along with the recent formulary listings, we believe it will allow us to improve accessibility, availability and adoption of biosimilars in the U.S. for the benefit of patients and the overall healthcare system.”
SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn), co-developed by Viatris and Biocon Biologics, are actually obtainable in the U.S. market. The presently marketed non-interchangeable SEMGLEE (insulin glargine) is anticipated to be phased out by the tip of the 2021 calendar 12 months.
Speaking concerning the launch, Jose Cotarelo, Viatris Head of North America, mentioned: “We are extremely proud to stay true to that promise by bringing to millions of people with diabetes these interchangeable insulin biosimilar treatment options. We are pleased to also offer a broad range of options to help patients, which are intended to maximize access to these important medicines, regardless of financial circumstances, insurance or channel.”
To additional develop entry to insulins, Viatris has established a spread of choices to assist sufferers, which incorporates, a affected person help program, which can present free drugs to eligible sufferers with demonstrated monetary want. Copay Program supplied for eligible commercially-insured sufferers, which can assist scale back out-of-pocket bills on prescriptions to as little as $0 per 30-day provide. Voucher for brand spanking new sufferers to obtain 5 free 3 ml pens or two free 10 ml vials. Also, cash-pay packages to scale back out-of-pocket prices when paying on the pharmacy counter.